Myriad Genetics, Inc. Share Price
NASDAQ: MYGN | Small CapMyriad Genetics, Inc. Stock Performance
Open $3.23 | Prev. Close $3.19 | Circuit Range N/A |
Day Range $3.18 - $3.29 | Year Range $2.74 - $8.57 | Volume 1,16,534 |
Average Traded $3.23 |
Myriad Genetics, Inc. Share Price Today
As of 10 August 2026, Myriad Genetics, Inc.'s share price is $3.25. The stock opened at $3.23, compared to its previous close of $3.19. During today's trading session, Myriad Genetics, Inc.'s share price traded between $3.18 and $3.29, with an average price of $3.23. Over the past 52 weeks, the stock has recorded a high of $8.57 and a low of $2.74. In terms of performance, Myriad Genetics, Inc.'s share price has declined by 29.55% over the last six months and is down 48.86% on a year-on-year basis.
Myriad Genetics, Inc. Share Price Chart
Myriad Genetics, Inc. Stock Fundamentals & Key Indicators
Market Cap $301.41M | PE Ratio (TTM) -0.82 | Dividend Yield N/A |
EPS (TTM) $-3.95 | Revenue (TTM) $824.50M | Return On Equity (TTM) -99.43% |
Profit Margin -44.38% | Debt to Equity 0.36 | Quarterly Earnings Growth YoY -23.98% |
Myriad Genetics, Inc. Quarterly Profit & Loss
All figures in USD
Myriad Genetics, Inc. Annual Profit & Loss
All figures in USD
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Myriad Genetics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $2.92 | $3.25 | +13.61% |
Jul 2026 | $5.78 | $2.87 | -49.78% |
Jun 2026 | $4.02 | $5.71 | +42.63% |
May 2026 | $4.72 | $4.00 | -15.61% |
Apr 2026 | $4.51 | $4.74 | +5.33% |
Mar 2026 | $5.08 | $4.50 | -2.60% |
Feb 2026 | $5.53 | $4.62 | -17.79% |
Jan 2026 | $6.20 | $5.62 | -8.62% |
Dec 2025 | $7.49 | $6.15 | -19.34% |
Nov 2025 | $8.28 | $7.63 | -5.03% |
Oct 2025 | $7.29 | $8.03 | +11.20% |
Sep 2025 | $6.42 | $7.22 | +13.43% |